Economic Dimensions of Personalized and Precision Medicine最新文献

The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy following a Major Cardiovascular Event 细胞色素P450 2C19药物基因组学信息对重大心血管事件后接受氯吡格雷治疗的患者的价值

Economic Dimensions of Personalized and Precision Medicine Pub Date : 2018-05-09 DOI: 10.7208/chicago/9780226611235.003.0010

R. Pulk, J. Graham, F. Lichtenberg, D. Maeng, Marc S. Williams, E. Wright

引用次数: 0

Measuring the Potential Health Impact of Personalized Medicine 测量个性化医疗对健康的潜在影响

Economic Dimensions of Personalized and Precision Medicine Pub Date : 2018-04-16 DOI: 10.7208/chicago/9780226611235.003.0007

Kristopher J. Hult

引用次数: 3

The Economic Value and Pricing of Personalized Medicine 个性化医疗的经济价值与定价

Economic Dimensions of Personalized and Precision Medicine Pub Date : 2018-04-02 DOI: 10.7208/chicago/9780226611235.003.0001

T. Philipson

引用次数: 3

Physicians’ Financial Incentives to Personalize Medicine 医生个性化医疗的经济激励

Economic Dimensions of Personalized and Precision Medicine Pub Date : 2018-04-02 DOI: 10.7208/chicago/9780226611235.003.0008

David H. Howard, J. Hockenberry, G. David

引用次数: 1

Economic Dimensions of Personalized and Precision Medicine in Asia 亚洲个体化和精准医疗的经济维度

Economic Dimensions of Personalized and Precision Medicine Pub Date : 1900-01-01 DOI: 10.7208/chicago/9780226611235.003.0009

引用次数: 0

Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies 孤儿药认定对制药生物技术公司IPO投资者有价值的无形资产

Economic Dimensions of Personalized and Precision Medicine Pub Date : 1900-01-01 DOI: 10.7208/chicago/9780226611235.003.0011

{"title":"Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies","authors":"","doi":"10.7208/chicago/9780226611235.003.0011","DOIUrl":"https://doi.org/10.7208/chicago/9780226611235.003.0011","url":null,"abstract":"Orphan Drug (OD) legislation has been implemented with regulatory and financial incentives to encourage the drug innovation to treat rare diseases. This study aims to test whether OD Designations (ODD) granted by the Food and Drug Administration (FDA) to pharmaceuticals and biotechnology start-up companies may be considered as relevant signals in, attracting entrepreneurial finance and increasing the amount invested at the time of the Initial Public Offering (IPO) in the US stock markets. Furthermore, ODD before going public may also influence the access to other relevant resources for start-ups companies as for instance venture capital investments, collaborative revenues and employees prior to IPO. We found that the signaling power of ODD is positively and statistically significant for IPO investors in stock markets: an ODD prior to an IPO increase the IPO proceeds by about 37,5%. Regression results also suggest that ODD are stronger than p tents applications to attract IPO investors and other valuable resources before that the company goes public. Scholar and policy implications are discussed in the light of the signaling theory and drug development policies","PeriodicalId":320470,"journal":{"name":"Economic Dimensions of Personalized and Precision Medicine","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130558463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic Translation of Genomic Science 基因组科学的治疗翻译

Economic Dimensions of Personalized and Precision Medicine Pub Date : 1900-01-01 DOI: 10.7208/chicago/9780226611235.003.0002

引用次数: 1